Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 1/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.49 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 4/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | STAT5B | P51692 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5864001 | 0.90 | PTPN1 (0.41) | PTGESALOX5NR1H4KEAP1NFE2L2 | |
| SCHEMBL5863342 | 0.86 | KEAP1 (0.41) | KEAP1NFE2L2STAT5B | |
| SCHEMBL5863628 | 0.85 | KEAP1 (0.38) | PTGESALOX5KEAP1NFE2L2STAT5B | |
| SCHEMBL5864114 | 0.84 | RAPGEF4 (0.41) | KEAP1NFE2L2STAT5B | |
| SCHEMBL5863735 | 0.82 | AKR1C3 (0.41) | PTGESKEAP1NFE2L2STAT5B | |
| SCHEMBL5863737 | 0.82 | AKR1C3 (0.41) | PTGESKEAP1NFE2L2STAT5B | |
| SCHEMBL5864104 | 0.81 | OPRM1 (0.41) | KEAP1 | |
| SCHEMBL5863804 | 0.80 | HRH1 (0.41) | KEAP1 | |
| SCHEMBL5863878 | 0.78 | OPRM1 (0.39) | KEAP1 | |
| SCHEMBL5864179 | 0.78 | SIGMAR1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7053212-B2 | Acyclic amide and sulfonamide ligands for the estrogen receptor | PFIZER INC. (US) | 2006-05-30 | — | — | US | disclosed |
| EP-1542967-A1 | AMIDE AND SULFONAMIDE LIGANDS FOR THE ESTROGEN RECEPTOR | Pfizer Products Inc. (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040110767-A1 | Acyclic amide and sulfonamide ligands for the estrogen receptor | PFIZER INC | 2004-06-10 | — | — | US | disclosed |
| WO-2004026823-A1 | AMIDE AND SULFONAMIDE LIGANDS FOR THE ESTROGEN RECEPTOR | PFIZER PRODUCTS INC. (US) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110767-A1 | Acyclic amide and sulfonamide ligands for the estrogen receptor | GHSR, GPER1, SSTR1 | PTGES 222/4885ALOX5 1384/4885NR1H4 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.